

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12125-002002	Application No.
	Applicant Jan Johansson		
	Filing Date	Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Sub-class	Filing Date If Appropriate
CMW	AA	5,688,651	11/1997	Solomon	435/7.1		
↓	AB	6,462,171	10/2002	Soto-Jara et al.	530/326		
↓	AC	6,534,036	03/2003	Collinge et al.	424/9.1		

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
CMW	AD	WO 98/30229	07/16/1998	PCT			X	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
CMW	AE	Arnoux et al. "The crystal structure of HasA, a hemophore secreted by <i>Serratia marcescens</i> " <i>Nat. Struct. Biol.</i> 6:516-520 (1999)
	AF	Barsukov et al. "Three-dimensional structure of proteolytic fragment 163-231 of bacterioopsin determined from nuclear magnetic resonance data in solution" <i>Eur. J. Biochem.</i> 206:665-672 (1992)
	AG	Bode et al. "Structure of astacin and implications for activation of astacins and zinc-ligation of collagenases" <i>Nature</i> 358:164-167 (1992)
	AH	Booth et. al. "Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis" <i>Nature</i> 385:787-793 (1997)
	AI	Cherfils et al. "Structure of the Sec7 domain of the Arf exchange factor ARNO" <i>Nature</i> 392:101-105 (1998)
	AJ	Chiti et al. "Designing conditions for <i>in vitro</i> formation of amyloid protofilaments and fibrils" <i>Proc. Natl. Acad. Sci. USA</i> 96:3590-3594 (1999)
	AK	Chou et al. "Prediction of the Secondary Structure of Proteins from their Amino Acid Sequence" <i>Adv. Enzymol.</i> 47:45-148 (1978)
	AL	Dobson "Protein misfolding, evolution and disease" <i>TIBS</i> 24:329-332 (1999)
	AM	Esler et al. "Point Mutations in the Central Hydrophobic Cluster of a Human $\beta$ -Amyloid Congener Disrupts Peptide Folding and Abolishes Plaque Competence" <i>Biochemistry</i> 35:13914-13921 (1996)
	AN	Gomis-Ruth et al. "Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor $\alpha$ convertase inhibitors" <i>Protein Sci.</i> 7:283-289 (1998)
	AO	Gustafsson et al. "Amyloid fibril formation by pulmonary surfactant protein C" <i>FEBS Letters</i> 464:138-142 (1999)
	AP	James et al. "Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform" <i>Proc. Natl. Acad. Sci. USA</i> 94:10086-10091 (1997)
	AQ	Johansson "Molecular determinants for amyloid fibril formation: lessons from lung surfactant protein C" <i>Swiss Medical Weekly</i> 133(19-20):275-282 (2003)
↓	AR	Johansson et al. "Pulmonary surfactant-associated polypeptide SP-C in lipid micelles: CD studies of intact SP-C and NMR secondary structure determination of depalmitoyl-SP-C(1-17)" <i>FEBS Lett.</i> 362:261-265 (1995)
Examiner Signature		Date Considered
/Cherie Woodward/		09/21/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12125-002002	Application No.
	Applicant Jan Johansson		
	Filing Date	Group Art Unit	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
CMW	AS	Johansson et al. "The NMR Structure of the Pulmonary Surfactant-Associated Polypeptide SP-C in an Apolar Solvent Contains a Valyl-Rich $\alpha$ -Helix" <i>Biochemistry</i> 33:6015-6023 (1994)
	AT	Kallberg et al. "Prediction of Amyloid Fibril-forming Proteins" <i>Journal of Biological Chemistry</i> 276:12945-12950 (2001)
	AU	Kelly et al. "2.8-A Structure of Penicillin-sensitive D-Alanyl Carboxypeptidase-transpeptidase from <i>Streptomyces</i> R61 and Complexes with $\beta$ -Lactams" <i>J. Biol. Chem.</i> 260:6449-6458 (1985)
	AV	Klunk et al. "Quantifying Amyloid $\beta$ -Peptide (A $\beta$ ) Aggregation Using the Congo Red-A $\beta$ (CR-A $\beta$ ) Spectrophotometric Assay" <i>Anal. Biochem.</i> 266:66-76 (1999)
	AW	Lansbury "Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease" <i>Proc. Natl. Acad. Sci. USA</i> 96:3342-3344 (1999)
	AX	LeVine "Thioflavine T interaction with synthetic Alzheimer's disease $\beta$ -amyloid peptides: Detection of amyloid aggregation in solution" <i>Prot. Science</i> 2:404-410 (1993)
	AY	Liemann et al. "Influence of Amino Acid Substitutions Related to Inherited Human Prion Diseases on the Thermodynamic Stability of the Cellular Prion Protein" <i>Biochemistry</i> 38:3258-3267 (1999)
	AZ	Mandel et al. "Identification of protein-protein interfaces by decreased amide proton solvent accessibility" <i>Proc. Natl. Acad. Sci. USA</i> 95:14705-14710 (1998)
	AAA	Näslund et al. "Correlation Between Elevated Levels of Amyloid $\beta$ -Peptide in the Brain and Cognitive Decline" <i>J. American Medical Association</i> 283:1571-1577 (2000)
	ABB	Pramanik et al. "Electrospray Ionization Mass Spectrometry for the Study of Non-covalent Complexes: an Emerging Technology" <i>J. Mass Spectrom</i> 33:911-920 (1998)
	ACC	Riek et al. "NMR structure of the mouse prion protein domain PrP(121-231)" <i>Nature</i> 382:180-182 (1996)
	ADD	Rosenzweig et al. "Geometry of the soluble methane monooxygenase catalytic diiron center in two oxidation states" <i>Chem. Biol.</i> 2:409-418 (1995)
	AEE	Salomon et al. "Nicotine inhibits amyloid formation by the beta-peptide" <i>Biochemistry</i> 35:13568-13578 (1996)
	AFF	Selkoe "The Origins of Alzheimer Disease" <i>J. American Medical Association</i> 283:1615-1617 (2000)
	AGG	Sipe "Amyloidosis" <i>Annu. Rev. Biochem.</i> 61:947-975 (1992)
	AHH	Smith et al. "Probing the Non-covalent Structure of Proteins by Amide Hydrogen Exchange and Mass Spectrometry" <i>J. Mass Spectrom</i> 32:135-146 (1997)
	AII	Soto et al. "Inhibition of Alzheimer's Amyloidosis by Peptides That Prevent $\beta$ -Sheet Conformation" <i>Biochem Biophys Res Commun</i> 226:672-680 (1996)
	AJJ	Tjernberg et al. "A Molecular Model of Alzheimer Amyloid $\beta$ -Peptide Fibril Formation" <i>J. Biol. Chem.</i> 274:12619-12625 (1999)
	AKK	Tjernberg et al. "Arrest of $\beta$ -Amyloid Fibril Formation by a Pentapeptide Ligand" <i>J. Biol. Chem.</i> 371:8545-8548 (1996)
	ALL	Vandenbussche et al. "Secondary Structure and Orientation of the Surfactant Protein SP-B in a Lipid Environment. A Fourier Transform Infrared Spectroscopy Study" <i>Biochemistry</i> 31:9169-9176 (1992)
↓	AMM	Wang et al. "Conformation of human serum apolipoprotein A-I(166-185) in the presence of sodium dodecyl sulfate of dodecylphosphocholine by H-NMR and CD. Evidence for specific peptide-SDS interactions" <i>Biophys J</i> 71:174-184 (1996)

Examiner Signature /Cherie Woodward/	Date Considered 09/21/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12125-002002	Application No.
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Jan Johansson	
		Filing Date	Group Art Unit
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
CMW	ANN	Zahn et al. "NMR solution structure of the human prion protein" <i>Proc. Natl. Acad. Sci. USA</i> 97:145-150 (2000)

Examiner Signature	/Cherie Woodward/	Date Considered	09/21/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			